In recent times, the results of coronary heart disease (CHD) have evidently improved, which can be to some extent credited to the use of innovative drugs and partly to the evolution of percutaneous coronary intervention (PCI). From percutaneous transluminal coronary angioplasty to the bare-metal stent and then to drug-eluting stent, every step of PCI is attention-grabbing to an interventional cardiologist, great development has been made for patients with heart disease.

In the last few years, some replacement devices for treating coronary heart disease have been developed. Undeniably, drug-coated balloon (DCB), which was recommended by 2014 ESC Guidelines on myocardial revascularization, is the brightest star among them. DCB involves a semi-compliant angioplasty balloon coated with an anti-proliferative agent that can exert antirestenotic efficacy by permeating into the vessel wall during balloon contact.

Drug-coated balloon (DCB) is an innovative device for PCI, which has validated encouraging results due to its uncommon characteristic of a high-concentration, rapid local delivery of an antirestenotic drug without the use of a durable polymer or metal stent. The concept of DCB depends on fast curing of the vessel wall due to the quick release of the medication. Additionally, smooth muscle cells exposed to the drug in a shorter duration can lead to a persistent effect in the initial days after angioplasty. DCB is made to have similar antirestenotic effects as a drug-eluting stent (DES) with additional flexibility and nothing remaining in the vessel.

Opto Circuits has been a forerunner in the development of drug-coated balloons. These are polymer-free drug-coated balloon catheters that reduce the stimulus of chronic inflammation and the trigger for delayed thrombosis. It has been proven to lessen the duration of post-process antiplatelet therapy.

Their brand DIOR has been a key success in the treatment of such coronary challenges as bifurcation lesions, small vessel stenting and the problems presented by in-stent restenosis.

The DIOR, made by EuroCor, was the first DCB to earn a CE mark clearance in 2007. The drug is embedded in its microporous balloon surface, which elutes during one-minute balloon expansion. A newer generation balloon uses shellac as a carrier.

DIOR is not an implant so no material is left behind. It can eliminate the stent-in-stent intervention and prevents additional stiffening of the stented artery. It shortens the dual antiplatelet therapy for up to 3 months. DIOR offers an alternative treatment in bifurcations, by using it inside branches. It has also shown excellent clinical outcomes in de novo lesions and small vessels without stenting.

The use of DIOR has also drastically reduced the duration of antiplatelet therapy to three months when compared to a drug-eluting stent which requires antiplatelet therapy of 12 months or more, thereby reducing post-procedure medication costs for the patients too.

Opto’s major business comes from their subsidiaries in the USA and Germany and these companies cater to America, Europe and South-East Asia. DIOR is the leading brand of Drug coated Balloon, this is the future of heart operations as many patients who don’t want to have foreign elements like stents in their body are moving to this product of Drug-Coated Balloon.

Worldwide hospitals prefer products manufactured from US or European markets. Criticare Subsidiary is into ICU vital Monitors – these brands are a household name in US dental hospitals. Indian market is flooded with imported machines from China and there is no service support. Opto is working on their subsidiaries in Germany and the USA during the current year and will venture into Indian markets next year with complete end to end service support. So currently the majority of Opto’s revenues comes from the USA, European markets and all products are sold across 150 countries.